VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ADPT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ADPTAdaptive Biotechnologies Corporation
$28.46$4.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksADPTBalance Sheet

Adaptive Biotechnologies Corporation (ADPT) Balance Sheet

9Y historyFree accessUpdated daily

Total debt rose to $409.0M against cash of $75.6M and a debt-to-equity ratio of 2.22, suggesting the capital structure is weakening even as the current ratio of 3.97 appears comfortable on paper.

Income StatementBalance SheetCash FlowRatios

ADPT Balance Sheet

Annual statement

ADPT Balance Sheet

Adaptive Biotechnologies Corporation (ADPT) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets392.69M300.19M283.75M410.19M562.15M402.75M726.91M612.69M180.72M205.25M
Cash & Short-Term Investments298.95M226.98M222.29M346.4M498.2M353.06M688.27M576.87M165.02M192.15M
Cash Only75.61M70.5M47.92M65.06M90.03M139.06M123.44M96.58M55.03M85.31M
Short-Term Investments223.34M156.49M174.37M281.34M408.17M214M564.83M480.29M109.99M106.84M
Accounts Receivable66.67M50.37M41.73M37.97M40.06M17.41M10.05M12.68M4.81M5.58M
Days Sales Outstanding65.7966.3785.1181.3978.941.1737.2754.3931.5252.99
Inventory10.05M9.82M8.44M14.45M14.45M19.26M14.06M9.07M7.84M4.79M
Days Inventory Outstanding48.9850.2342.7469.891.1142.61227.83148.61145.46111.55
Other Current Assets17.01M13.02M11.29M11.37M9.44M00000
Total Non-Current Assets290.43M212.55M255.62M250.95M294.47M520.6M389.5M299.61M151.97M157.24M
Property, Plant & Equipment65.96M74.72M94.38M120.32M164.21M172.94M139.04M60.35M19.13M13.95M
Fixed Asset Turnover4.25x3.71x1.90x1.42x1.13x0.89x0.71x1.41x2.91x2.76x
Goodwill118.97M118.97M118.97M118.97M118.97M118.97M118.97M118.97M118.97M118.97M
Intangible Assets456K1.73M3.42M5.13M6.83M8.53M10.22M11.93M13.63M15.32M
Long-Term Investments147.36M15.92M33.66M00217.15M118.53M105.44M247K8.9M
Other Non-Current Assets3.82M1.21M5.18M6.52M4.46M3.01M2.74M2.92M247K86K
Total Assets683.12M512.74M539.38M661.13M856.62M923.34M1.12B912.3M332.69M362.49M
Asset Turnover0.51x0.54x0.33x0.26x0.22x0.17x0.09x0.09x0.17x0.11x
Asset Growth %62.34%-4.94%-18.42%-22.82%-7.23%-17.29%22.37%174.22%-8.22%-
Total Current Liabilities98.97M89.92M98.05M88.02M109.79M113.81M105.2M78.31M22.8M21M
Accounts Payable6.53M6.47M7.26M7.72M8.08M3.31M3.24M4.45M1.79M1.96M
Days Payables Outstanding32.8133.0836.7937.2950.9524.4852.4472.9733.2745.72
Short-Term Debt013.56M00000000
Deferred Revenue (Current)207.84M45.19M55.69M48.63M64.11M80.46M73.32M60.99M12.7M14.05M
Other Current Liabilities07.7M16.7M13.69M15.94M15.64M11.95M8.49M3.67M1.93M
Current Ratio3.97x3.34x2.89x4.66x5.12x3.54x6.91x7.82x7.93x9.77x
Quick Ratio3.87x3.23x2.81x4.50x4.99x3.37x6.78x7.71x7.58x9.54x
Cash Conversion Cycle81.9683.5291.06113.9119.04159.3212.66130.03143.7118.82
Total Non-Current Liabilities400.26M197.82M238.84M264.84M282.73M205.44M267.95M262.95M568M566.1M
Long-Term Debt335.38M196.79M000000561.19M0
Capital Lease Obligations270.6M70.23M79.15M89.39M98.77M106.69M104.33M36.61M00
Deferred Tax Liabilities00000000-561.19M0
Other Non-Current Liabilities20K-70.21M132.43M130.66M125.36M007.01M6.1M566.1M
Total Liabilities499.23M287.74M336.89M352.86M392.52M319.24M373.15M341.26M590.8M587.11M
Total Debt408.97M280.58M89.39M98.77M108M111.74M107.86M36.61M561.19M561.67M
Net Debt333.36M210.09M41.47M33.71M17.97M-27.32M-15.57M-59.97M506.16M476.37M
Debt / Equity2.22x1.25x0.44x0.32x0.23x0.18x0.15x0.06x--
Debt / EBITDA-12.44x---------
Net Debt / EBITDA-10.14x---------
Interest Coverage-4.99x-4.05x-12.78x-15.33x-46.28x-----
Total Equity183.89M225M202.49M308.28M464.1M604.1M743.27M571.04M-258.11M-224.62M
Equity Growth %2.95%11.12%-34.32%-33.57%-23.18%-18.72%30.16%321.24%-14.91%-
Book Value per Share0.981.481.382.143.264.305.664.59-2.45-2.13
Total Shareholders' Equity176.21M218.79M202.71M308.4M464.17M603.99M743.27M571.04M-258.11M-224.62M
Common Stock16K15K14K14K14K14K14K12K1K1K
Retained Earnings-1.42B-1.36B-1.3B-1.14B-919.08M-718.89M-511.61M-365.48M-295.91M-249.42M
Treasury Stock0000000000
Accumulated OCI-1.28M253K166K215K-4.12M-1.14M893K671K-107K-166K
Minority Interest7.68M6.21M-224K-121K-67K110K0000

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Thin liquidity against debt

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Leverage Rising as Cash Lags Growth

Based on reported quarterly balance sheets, ADPT's total debt climbed from $84.4M in 2025Q2 to $409.0M in 2026Q3 while cash fell to $75.6M, a mismatch that suggests the balance sheet is weakening even as the top line expands.

The jump in debt to $409.0M against roughly $176M of equity lifts debt-to-equity to 2.22, a sharp reversal from the sub-0.5 leverage seen through most of 2025. This pattern may indicate that the company is financing operations with borrowings rather than internally generated cash, which investors should monitor closely. Whether this reflects strategic capital deployment or a necessity-driven funding gap warrants further investigation of the debt agreements.

Debt Surge Outpaces Liquidity Buffer

According to recent SEC filings, ADPT's debt reached $410.5M in 2026Q2 against cash of $169.9M, leaving a gap that a company still posting negative trailing margins may find difficult to close without new financing.

Debt-to-equity peaked at 2.72 in 2026Q2 before easing to 2.22, but the level remains high for a company with a trailing operating margin of -20.6%. Refinancing risk and covenant exposure cannot be assessed from the supplied data, and the absence of maturity or interest detail limits conclusions. The debt load appears to depend on sustained revenue execution to remain serviceable.

Current Ratio Strong, Cash Thin

As reported in financial statements, ADPT's current ratio of 3.97 in 2026Q3 looks comfortable on paper, yet cash of $75.6M is modest relative to the company's ongoing operating losses and debt service needs.

A current ratio near 4 suggests short-term assets comfortably exceed short-term obligations, but the composition of current assets is not disclosed and may be weighted toward receivables rather than cash. Given that cash has ranged between $38M and $170M over the period, the liquidity runway appears limited relative to burn. Investors should treat the ratio as a partial signal and focus on cash conversion.

Accumulated Deficit Dwarfs Shareholder Equity

Based on EDBL's reported figures, retained earnings sit near -$1.4B against equity of only $176.2M, indicating that cumulative losses have consumed the vast majority of capital contributed by shareholders over time.

Equity has compressed from $241.6M in 2024Q2 to $176.2M in 2026Q3, consistent with persistent losses that have not been offset by profitability. The scale of the accumulated deficit implies that any future equity raise would likely be dilutive to existing holders. Stock-based compensation and share issuance are not fully visible in this dataset, so the true dilution profile remains uncertain.

Reported Equity Stability May Mask Risk

Headline leverage metrics may understate the true balance sheet pressure, as deferred revenue of $60.4M and recent debt additions are not reflected in any single ratio and could alter the apparent liquidity picture.

Deferred revenue has risen from $42.5M to $60.4M over recent quarters, which may represent customer prepayments that improve near-term cash but create future performance obligations. Conversely, the debt added in 2026 may carry terms not visible in the summary data. Interpreting the current ratio without separating restricted or non-cash current assets could overstate true liquidity.

ADPT — Frequently Asked Questions

Quick answers to the most common questions about buying ADPT stock.

What are the total assets of Adaptive Biotechnologies Corporation (ADPT)?

As of 2025, Adaptive Biotechnologies Corporation (ADPT) had total assets of $512.7M including $300.2M in current assets.

How much debt does Adaptive Biotechnologies Corporation (ADPT) have?

Adaptive Biotechnologies Corporation (ADPT) carries total debt of $280.6M, offset by $227.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Adaptive Biotechnologies Corporation?

Adaptive Biotechnologies Corporation (ADPT) has total shareholders' equity (book value) of $218.8M ($1.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Adaptive Biotechnologies Corporation's current ratio and liquidity?

Adaptive Biotechnologies Corporation (ADPT) reported a current ratio of 3.34x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.